Genentech letter warns of stroke risk with ranibizumab

Article

South San Francisco-Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD).

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
ChatGPT may have a future use in glaucoma

ChatGPT may have a future use in glaucoma

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Podcast
Therapeutic in development to take on diabetic macular edema

Therapeutic in development to take on diabetic macular edema

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

Podcast
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Article
Stress resilience–enhancing drugs: New class of small molecules holds promise

Stress resilience–enhancing drugs: New class of small molecules holds promise

Article
© 2024 MJH Life Sciences

All rights reserved.